Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03078192 · ClinicalTrials.gov registry record · Phase 2
Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging
A Phase 2 study, sponsored by Bastiaan Driehuys.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT03078192 is a Phase 2 study that has completed, run by Bastiaan Driehuys. The registered enrollment target is 62 participants.
The verdict
NCT03078192, a Phase 2 study, has completed, sponsored by Bastiaan Driehuys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study seeks to deploy several forms of 129Xe MRI contrast as well as emerging conventional proton MRI technqiues for imaging lung structure and perfusion. Specifically, the 129Xe MRI scans will provide 3D images of ventilation and gas exchange, and spectroscopic indices will be evaluated to test gas exchange dynamics with high temporal resolution. The conventional 1H MRI scans will include a free-breathing ultra-short echo time (UTE) scan that provides images similar to that of a CT scan. In addition, to characterize perfusion and vascular dimensions directly, patients will undergo a gadolinium-enhanced perfusion scan.
Interventions
- DEVICE MRI
- DRUG GE-141, Hyperpolarized 129Xenon gas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2017-05-03 |
| Est. Completion | 2020-10-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03078192
The ClinicalTrials.gov registry entry for NCT03078192 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bastiaan Driehuys, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRI is the first listed.
NCT03078192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03078192 about?
NCT03078192 is a clinical study titled "Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging". This study seeks to deploy several forms of 129Xe MRI contrast as well as emerging conventional proton MRI technqiues for imaging lung structure and perfusion. Specifically, the 129Xe MRI scans will provide 3D images of ventilation and gas exchange, and spectroscopic indices will be evaluated to tes...
What is the current status of trial NCT03078192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2017-05-03. Estimated completion is 2020-10-22.
What interventions are being tested in trial NCT03078192?
The interventions under investigation include: MRI (DEVICE), GE-141, Hyperpolarized 129Xenon gas (DRUG).
Who is sponsoring clinical trial NCT03078192?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.